Chromium-containing traditional Chinese medicine, Tianmai Xiaoke tablet improves blood glucose through activating insulin-signaling pathway and inhibiting PTP1B and PCK2 in diabetic rats

Journal of Chinese Integrative Medicine

Volumn 12, Issue 3, 2014, Pages 162-170

  Zhang, Qian ^a   Xiao, Xin Hua ^a   Li, Ming ^a   Li, Wen Hui ^a   Yu, Miao ^a   Zhang, Hua Bing ^a   Ping, Fan ^a   Wang, Zhi Xin ^a   Zheng, Jia ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Chromium; Diabetes mellitus; Gluconeogenesis; Glycolysis; Insulin signaling pathway; Rats; TCA cycle

Indexed keywords

CHROMIUM PICOLINATE; FORKHEAD TRANSCRIPTION FACTOR; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; MESSENGER RNA; ONCOPROTEIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); PROTEIN TYROSINE PHOSPHATASE 1B; TIANMAI XIAOKE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; BODY WEIGHT; CHINESE MEDICINE; CONTROLLED STUDY; DNA MICROARRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; POLYMERASE CHAIN REACTION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SKELETAL MUSCLE;

ANIMALS; BLOOD GLUCOSE; CHROMIUM; DIABETES MELLITUS, TYPE 2; INSULIN; INSULIN RESISTANCE; MALE; MEDICINE, CHINESE TRADITIONAL; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TABLETS;

EID: 84901424350     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2095-4964(14)60020-0     Document Type: Article

References (26)

1. O'Brien RM, Granner DK. Regulation of gene expression by insulin. Physiol Rev. 1996; 76(4): 1109-1161.
2. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J; China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med. 2010; 362(12): 1090-1101.
3. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; DCCT/EDIC Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25): 2643-2653.
4. Cefalu W, Hu F. Role of chromium in human health and in diabetes. Diabetes Care. 2004; 27(11): 2741-2751.
5. Shao C, Lü XF, Xiao XH, Xu ZR, Yang ZJ, Wang P, Liu XL, Yang WY. Efficacy of Tianmaixiaoke tablets in the treatment of newly diagnosed type 2 diabetes mellitus in China. Zhonghua Yi Xue Za Zhi. 2012; 92(22): 1522-1526. Chinese with abstrat in English.
6. Anderson RA, Cheng N, Bryden NA, Polansky MM, Cheng N, Chi J, Feng J. Elevated intakes of supplemental chromium improves glucose and insulin variables in individuals with type 2 diabetes. Diabetes. 1997; 46(11): 1786-1791.
7. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois TM, Reaven GM. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism. 2000; 49(11): 1390-1394.
8. Huang JH, Huang XH, Chen ZY, Zheng QS, Sun RY. Dose conversion among different animals and healthy volunteers in pharmacological study. Zhongguo Lin Chuang Yao Li Xue Yu Zhi Liao Xue. 2004; 9(9): 1069-1072. Chinese with abstrat in English.
9. Gao LH, Liu Q, Liu SN, Chen ZY, Li CN, Lei L, Sun SJ, Li LY, Liu JL, Shen ZF. A refined-Jinqi-Jiangtang tablet ameliorates prediabetes by reducing insulin resistance and improving β cell function in mice. J Ethnopharmacol. 2014; 151(1): 675-685.
10. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998; 95(25): 14863-14868.
11. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003; 4(5): P3.
12. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol. 2003; 4(10): R70.
13. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-Δ ΔC(T) method. Methods. 2001; 25(4): 402-408.
14. Anderson RA, Roussel AM, Zouari N, Mahjoub S, Matheau JM, Kerkeni A. Potential antioxidant effects or zinc and chromium supplementation in people with type 2 diabetes mellitus. J Am Coll Nutr. 2001; 20(3): 212-218.
15. Kleefstra N, Houweling ST, Bakker SJ, Verhoeven S, Gans QO, Meyboorn-de Jong B, Bilo HJ. Chroumium treatment has no effect in patients with type 2 diabetes in a Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care. 2007; 30(5): 1092-1096.
16. Komorowski J, Juturu V. Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profle: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance: response to Gunton et al. Diabetes Care. 2005; 28(7): 1842-1843.
17. Albarrancin CA, Fugua BC, Evans JL, Goldfne ID. Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. Diabetes Metab Res Rev. 2008; 24(1): 41-51.
18. Martin J, Wang ZQ, Zhang XH, Wachtel D, Volaufova J, Matthews DE, Cefalu WT. Chromium picolinate supplementation attenuates body weight gain and increase insulin sensitivity in subjects with type 2 diabetes. Diabetes Care. 2006; 29(8): 1826-1832.
19. Wang ZQ, Zhang XH, Russell JC, Hulver M, Cefalu WT. Chromium picolinate enhance skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR: LA-cp rats. J Nutr. 2006; 136(2): 415-420.
20. Yang X, Li S Y, Dong F, Ren J, Sreejayan N. Insulin-sensitizing and cholesterol-lowering effects of chromium (D-Phenylalanine)3. J Inorg Biochem. 2006; 100(7): 1187-1193.
21. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, Normandin D, Cheng A, Himms-Hagen J, Chan CC, Ramachandran C, Gresser MJ, Tremblay ML, Kenedy BP. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 1999; 283(5407): 1544-1548.
22. Klaman LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabolotny JM, Moghal N, Lubkin M, Kin YB, Sharpe AH, Stricker-Krongrad A, Shulman GI, Neel BG, Kahn BB. Increased energy expenditure, decreased adiposity, and tissue-specifc insulin sensitivity in protein-tyrosine phosphatase 1B-defcient mice. Mol Cell Biol. 2000; 20(15): 5479-5489.
23. Zinker BA, Rondinone CM, Trevillyan JM, Gum RJ, Clampit JE, Waring JF, Xie N, Wilcos D, Jacobson P, Frost L, Kroeger PE, Reilly RM, Koterski S, Opgenorth TJ, Ulrich RG, Crosby S, Butler M, Murray SF, McKay RA, Bhanor S, Monia BP, Jirousek MR. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci U S A. 2002; 99(17): 11357-11362.
24. Gum RJ, Gaede LL, Koterski SL, Heindel M, Clampit JE, Zinker BA, Trevillyan JM, Ulrich RG, Jirousek MR, Rondinone CM. Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice. Diabetes. 2003; 52(1): 21-28.
25. Consdi A, Nurjhan N. Contribution of gluconeogenesis to overall glucose output in diabetic and nondiabetic men. Ann Med. 1990; 22(3): 191-195.
26. Valera A, Pujol A, Pelegrin M, Bosch F. Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes. Proc Natl Acad Sci U S A. 1994; 91(19): 9151-9154.